Updated regulatory guidelines for enhanced safety features associated with enteral syringe are expected to propel growth of the market

Seattle, WA -- (SBWire) -- 09/25/2019 --Enteral syringe are used to administer drugs and other nutritional therapy rectal, oral, and sublingual route of administration. Generally, they are available in the rage of 1 ml to 60 ml and are commonly used in hospitals, clinics, and homes. Manufacturers develop eternal syringes in accordance with the new standards specified by international standard ISO 80369-3. These syringes are manufactured with purple plunger, which indicates that medication in the syringe should be administered enteral route. The purple color is typically used to separate these syringes from IV syringes. These syringes typical help to inject drugs into gastro-intestinal tract. However, their major use is for delivering oral liquid medication and nutrition. Moreover, these syringes are used for enteral feedings. These syringes have a wide range of applications are used to administer liquid medicine in a patient where does cannot be precisely measure using a medical cup or spoon, especially in infants and children. These syringes are widely available in single-use as well as home use syringes.

The global enteral syringe market size was valued at US$ 575.6 million in 2017 and is expected to witness a CAGR of 4.9% over the forecast period (2018 – 2026).

Request Sample Copy of this Research Report - https://www.coherentmarketinsights.com/insight/request-sample/2398

Increasing number of neonatal intensive care unit admissions and critical care is expected to propel growth of the global enteral syringe market. This growth is attributed to patients admitted to critical care and newborns admitted to neonatal intensive care (due to premature birth or other complications) unable to swallow medicine or take nutrition. For instance, according to Bliss Organization stats, over 95,000 newborns are admitted to neonatal units in the U.K., annually due to premature birth (before 37 weeks of pregnancy) or due to full term (after 37 weeks) yet sick birth. Moreover, according to same source, around 1 in every 8 newborns in the U.K. are admitted to neonatal units, annually.

Moreover, growing geriatric population is expected to drive the global enteral syringe market growth during the forecast period. People aged 60 years and above are more prone to illness or injuries that often need hospital admission and typically medical administration via enteral syringe. For instance, according to United Nations report: World Population Prospect-The 2017 Revision, global geriatric population is expected to increase from 962 million in 2017 (13% of worldwide population) to 1.3 billion by 2030 and will reach to 2.1 billion by 2050. Furthermore, according to same source, global geriatric population is currently increasing at a rate of 3% annually and around all regions. However, according to the same source, Africa are expected to register geriatric population of over 25% by 2050.

Regulatory guidelines for design and manufacturing of enteral devices including enteral syringe were recently updated by various regulatory bodies. In 2015, new design standards were introduced in enteral feeding sets, enteral syringes, and enteral feeding tubes referred as ENFit. ENFit is a new connection standard that is developed by an international group of clinicians, manufacturers body Global Enteral Device Supplier Association (GEDSA), and regulators under aegis of Stay Connected initiative to prevent tubing misconnections and patient injury. Tubing misconnection occurs when enteral devices are connected to non-enteral devices such as IV lines, urinary catheters, and ventilator tubing. Global Enteral Device Supplier Association (GEDSA) promotes safe use of enteral devices including syringes. Market players that comply with ENFit standard design are receiving 510(k) clearance from the U.S Food and Drug Administration (U.S. FDA). For instance, in 2016, NeoMed and Medtronic received the U.S FDA 510(k) clearance for low dose tip ENFit syringes. NeoMed has offered royalty-free access of its design to all syringe manufacturers. Therefore, several manufacturers can implement this design standard to promote safe use of these devices, which in turn is expected to increase adoption of enteral syringes.

Get PDF Brochure of Research Report - https://www.coherentmarketinsights.com/insight/request-pdf/2398

Detailed Segmentation:

By Product Type:

Single Use Enteral Syringes

Home Use Enteral Syringes

Catheter Tip Syringes

Others

By Application:

Cancer

Malnutrition

Neurological Disease

GI Related Disease

Others

By Patient Group:

Neonates and Pediatrics

Adults

By End User:

Hospitals and Ambulatory care centers

Home-based user

Key players operating in the global enteral syringe market include, B. Braun Melsungen AG, GBUK Enteral Ltd., Thermo Fischer, Inc., Koninklijke Philips N.V., Miktell Ltd., Baxter International, Inc., Cardinal Health, Inc., Terumo Corporation, Kentec Medical, Inc., Vygon S.A., and others.

To view the original version on The Express Wire visit https://www.coherentmarketinsights.com/market-insight/enteral-syringe-market-2398

About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.